

CANADIAN DIABETIC ASSOCIATION TARGETS for GLYCEMIC CONTROL

Value	Target for Type 1 and 2 diabetes
Hemoglobin A _{1c} fraction (A1C %)	≤ 7
FPG/Pre-meal glucose, mmol/L	4-7
2 hour post-meal glucose, mmol/L	5-10 (5-8 if A1C targets not being met)

FPG = Fasting plasma glucose

ORAL ANTIDIABETIC MEDICATION COMPARISON

Class	Example	Mechanism of Action	A1C ↓	Side Effects/Contraindications	Hypoglycemia Risk
Sulfonyl-urea	Glyburide ¹ Gliclazide ¹ Tolbutamide ¹	↑ insulin secretion by pancreas	1.5-2%	↑ weight, hypoglycemia; contraindicated if sulfa allergy	↑
Meglitinide	Repaglinide Nateglinide	↑ insulin secretion by pancreas	1.5-2%	↑ weight, hypoglycemia	↑
Biguanide	Metformin ¹	↓ hepatic glucose output, Insulin sensitizer	1.5-2%	Diarrhea, Lactic acidosis; C/I if eGFR <30 mL/min	↔
Thiazolidine-dione	Rosiglitazone Pioglitazone ¹	Insulin sensitizer	1-1.5%	Edema, CHF; contraindicated if ALT > 2.5x normal	↔
alpha-glucosidase Inhibitor	Acarbose ¹	Inhibits breakdown of di- and polysaccharides in intestine	0.5-1%	GI side effects; contraindicated if GI dysfunction	↔
Incretin	Linagliptin ¹	↑ insulin; ↓ glucagon	0.5-1%	Nasopharyngitis, headache	↔
SGLT-2 Inhibitor	Canagliflozin, Dapagliflozin	↑ glucosuria	0.6%	Infections (UTI, vaginal), ↓ BP	↔

¹formulary drug